Current Report Filing (8-k)
July 08 2021 - 4:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF
1934
Date of Report (Date of earliest event reported): July 6, 2021
VistaGen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
NEVADA
|
000-54014
|
20-5093315
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
343 Allerton Ave.
South San Francisco, California 94090
|
(Address of principal executive offices)
|
(650) 577-3600
(Registrant’s telephone number, including area
code)
Not Applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a
-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d -2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e -4(c))
Securities registered pursuant to Section 12(b) of the
Act:
Title
of each class
|
Trading
Symbol(s)
|
Name of
each exchange on which registered
|
Common
Stock, par value $0.001 per share
|
VTGN
|
Nasdaq
Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR 240.12b-2)
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act ☐
Item 5.02 Election of Directors.
On July
6, 2021, Mary L. Rotunno J.D. was appointed to serve on the Board
of Directors (the “Board”) of VistaGen Therapeutics,
Inc. (the “Company”). Ms. Rotunno was deemed
to be an “independent director,” as such term is
defined in Listing Rule 5605 of the Nasdaq Stock Market. A copy of
the press release announcing Ms. Rotunno’s appointment is
attached to this Current Report on Form 8-K as Exhibit
99.1.
Ms.
Rotunno, age 61, has served as General Counsel of El
Camino Health, a $1 billion revenue health care system, since
January 2014, and has served as a Member of the Executive
Leadership Team at El Camino Health since August 2015. Ms. Rotunno
is also Board Chair and a member of Audit, Executive/Governance and
Nominations Committees for health care provider, Momentum for
Health, located in San Jose, California. Before joining
El Camino Health, Ms. Rotunno spent over 11 years as Senior Counsel
and Client Service Leader for Common Spirit Health, formerly
Dignity Health, in California’s San Francisco Bay Area. Prior
to Dignity Health, she held various legal roles at Varian Medical
Systems, Manatt, Phelps & Phillips, Golden Living, and
Pillsbury Winthrop Shaw Pitman. Ms. Rotunno graduated with honors
from the University of Illinois with a Bachelor of Science in
Nursing. She worked as a registered nurse before earning her Juris
Doctor degree, cum laude, from the University of California,
Hastings College of Law, San Francisco. She obtained
certification by the Women’s Corporate Board Readiness
Program at Santa Clara University and completed the Hastings
Leadership Academy for Women and Dignity Health Ministry Leadership
Program.
There
are no arrangements or understandings between Ms. Rotunno and any
other person pursuant to which she was selected as a director, and
Ms. Rotunno is not a participant in any related party transaction
required to be reported pursuant to Item 404(a) of Regulation
S-K.
In
connection with her appointment, the Company entered into
an Indemnification Agreement (the “Indemnification Agreement”) with
Ms. Rotunno. The Indemnification Agreement requires the
Company to indemnify Ms. Rotunno to the fullest extent permitted
under Nevada law against liability that may arise by reason of her
service to the Company and to advance certain expenses incurred as
a result of any proceeding against her as to which she could be
indemnified.
The
foregoing description of the Indemnification Agreement is
not complete and is qualified in its entirety by reference to the
full text of the Indemnification Agreement, which is attached
as Exhibit 10.1 to this Current Report on Form 8-K and
incorporated into this Item 5.02 by reference.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits.
See
Exhibit Index.
Signatures
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
VistaGen
Therapeutics, Inc.
|
|
|
|
Date:
July 8, 2021
|
By:
|
/s/ Shawn K. Singh
|
|
|
Shawn
K. Singh
Chief
Executive Officer
|
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
|
|
Indemnification
Agreement, dated July 6, 2021, by and between VistaGen
Therapeutics, Inc. and Mary L. Rotunno
J.D.
|
|
|
Press
Release issued byVistaGen Therapeutics, Inc., dated July 7,
2021
|
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2023 to Apr 2024